Ascletis Pharma Announces Preclinical Success of ASC36_35 FDC with Superior Weight Loss Results at EASD 2026
Ascletis Pharma Inc. (Stock Code: 1672), a biopharmaceutical company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, has released a voluntary announcement regarding a significant business development. The company will present promising preclinical data for its new obesity treatment candidate, ASC36_35 FDC, at the upcoming 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan, Italy, scheduled for September 28 to October 2, 2026.
Key Highlights for Investors
- ASC36_35 FDC Overview: ASC36_35 FDC is a once-monthly subcutaneous injection co-formulation, combining ASC36 (an amylin receptor agonist) and ASC35 (a GLP-1R/GIPR agonist). This new therapy targets three validated pathways for obesity treatment: the amylin receptor, GLP-1R, and GIPR.
- Preclinical Results: In a diet-induced obese (DIO) animal model, ASC36_35 FDC demonstrated superior weight loss compared to the combination of eloralintide and tirzepatide, both established agents in the obesity space.
- Technology Platform: The drug utilizes Ascletis’ proprietary Self-Assembling Lipid Depot (SALD) formulation and Ultra-Long-Acting Platform (ULAP) technology, enabling its once-monthly dosing and potentially improving patient compliance and convenience.
- Recognition at EASD: The selection for oral discussion at a major international diabetes conference highlights the scientific and commercial importance of the results. The presentation (Abstract Number 768) will take place on October 1, 2026, between 14:00 – 15:00 CEST.
- Potential Competitive Advantages: If ASC36_35 FDC’s preclinical superiority translates into clinical results, Ascletis could be a front-runner in the multi-billion-dollar obesity treatment market, which is currently dominated by agents like tirzepatide and GLP-1 analogues.
Potential Price-Sensitive Information
- The announcement confirms that ASC36_35 FDC is a potentially first-in-class drug candidate for obesity, targeting multiple pathways and offering once-monthly dosing.
- Positive preclinical data demonstrating superior efficacy to leading competitors (eloralintide/tirzepatide) could significantly enhance Ascletis’ commercial prospects and investor sentiment.
- The news of selection for oral discussion at the EASD Annual Meeting is a strong validation from the scientific community, increasing the visibility and credibility of Ascletis’ pipeline.
- Ascletis explicitly states that it cannot guarantee ultimate successful development, manufacturing, or commercialization of ASC36_35 FDC, ASC35 and/or ASC36, highlighting the inherent risks typical for biotech development.
Leadership Comments
Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis, commented, “We believe the co-formulation of ASC36 and ASC35 has the potential to lead to greater weight loss in people with obesity than eloralintide/tirzepatide combination can achieve, based on these preclinical data. The selection of these data for oral discussion at EASD 2026 reflects the importance of advancing new treatment options for patients with obesity.”
Board Composition
The current board consists of Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu as executive directors, and Dr. Yizhen Wei, Mr. Jiong Gu, and Ms. Lin Hua as independent non-executive directors.
Investor Takeaway
This announcement is potentially price-sensitive as it signals a breakthrough in obesity treatment with strong preclinical efficacy, scientific validation, and potential competitive differentiation. Success in clinical trials could result in significant commercial upside for Ascletis Pharma. However, investors should note the standard biotech risks: there is no guarantee of future success in development and commercialization.
Disclaimer: The above article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, including but not limited to successful drug development, regulatory approval, and commercial viability. Investors are advised to conduct their own due diligence and consult professional advisors before making any investment decisions.
